ARCA Biopharma, Inc. (NASDAQ: ABIO) Brings Precision Medicine Closer to Reality

  • Drug candidate for top cause of death in the United States
  • Genetically-targeted therapy increases chances of recovery
  • Interim efficacy analysis soon to be conducted by the Data Safety Monitoring Board

Atrial fibrillation affects up to six million people in the U.S. The condition, if untreated, can lead to blood clots, stroke, heart failure and other heart-related complications, but many medications currently in use to treat it come with worrying side effects, perhaps because of their one-size-fits-all approach. In an effort to mitigate the unwanted, unintended action of these agents, ARCA Biopharma, Inc. (NASDAQ: ABIO) is applying a precision medicine approach, developing genetically-targeted therapies for cardiovascular diseases, as it works to bring its lead candidate for atrial fibrillation, Gencaro™, to market. The company believes that by tailoring medical treatment to the individual genetic characteristics of patients, more effective therapies will be enabled, patient outcomes will be improved and health care costs will go down.

Atrial fibrillation (AFib) is the most common kind of heart arrhythmia, a condition where the heart beats too fast, too slow, or in an irregular fashion. In a heart suffering from AFib, the regular pumping action of its upper chambers, the atria, is impaired. As a result, blood flow to the lower chambers, the ventricles, is impeded. AFib increases a person’s risk for stroke by four to five times compared with…


More from NetworkNewsWire

Net Element, Inc. (NASDAQ: NETE) Proposes a Reverse Split of its Common Stock to Increase Valuation

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Findings Set Stage for Future Cannabinoid Compound Studies

Absent Federal Banking Support, Cannabis Market Shows Growing Interest in Proprietary Bitcoin Payment Solutions

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s